Education
About Us
Working with TipRanks
Follow Us
Serina Therapeutics (SER)
:SER
SER Analyst Ratings
Moderate Buy
1 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
SER Stock 12 Month Forecast
Average Price Target
$11.00
▲(300.00% Upside)
| Highest Price Target$11.00 | Average Price Target$11.00 | Lowest Price Target$11.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
JonesTrading
$11
Buy
300.00%
Upside
Reiterated
11/14/25
Analysts' Top Healthcare Picks: Serina Therapeutics (SER), Cybin (CYBN)We reiterate our Buy rating and a $11PT. Investment Thesis. SER-252 (POZ-Apomorphine) will advance into and through clinical development, achieving comparable efficacy to currently approved infusion systems with improved tolerability (fewer infusion site reactions) and ease of use (via the enFuse device) in advanced Parkinson's Disease patients. SER-252 will provide clinical validation for the broader POZ platform, which will support longer term company growth with a pipeline of POZ-enabled small molecule assets and partnership-enabling POZ-RNA and/ or POZ-ADC assets.
H.C. Wainwright
$15
Buy
445.45%
Upside
Reiterated
08/28/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
JonesTrading
$11
Buy
300.00%
Upside
Reiterated
11/14/25
Analysts' Top Healthcare Picks: Serina Therapeutics (SER), Cybin (CYBN)We reiterate our Buy rating and a $11PT. Investment Thesis. SER-252 (POZ-Apomorphine) will advance into and through clinical development, achieving comparable efficacy to currently approved infusion systems with improved tolerability (fewer infusion site reactions) and ease of use (via the enFuse device) in advanced Parkinson's Disease patients. SER-252 will provide clinical validation for the broader POZ platform, which will support longer term company growth with a pipeline of POZ-enabled small molecule assets and partnership-enabling POZ-RNA and/ or POZ-ADC assets.
H.C. Wainwright
$15
Buy
445.45%
Upside
Reiterated
08/28/25
Best Analysts Covering Serina Therapeutics
1 Month
xxx
Success Rate
3/4 ratings generated profit
Average Return
-2.23%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of -2.23% per trade.
3 Months
xxx
Success Rate
1/4 ratings generated profit
Average Return
-12.70%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 25.00% of your transactions generating a profit, with an average return of -12.70% per trade.
1 Year
Success Rate
0/4 ratings generated profit
Average Return
-42.25%
reiterated a buy rating last month
Copying Justin Walsh's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -42.25% per trade.
2 Years
xxx
Success Rate
0/4 ratings generated profit
Average Return
-42.25%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -42.25% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
SER Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
2
3
2
2
1
Buy
0
0
0
0
0
Hold
10
12
9
5
2
Sell
1
1
2
3
5
Strong Sell
0
0
0
0
0
total
13
16
13
10
8
Each month's total comprises the sum of three months' worth of ratings.
SER Financial Forecast
SER Stock Forecast FAQ
What is SER’s average 12-month price target, according to analysts?
Based on analyst ratings, Serina Therapeutics’s 12-month average price target is 11.00.
What is SER’s upside potential, based on the analysts’ average price target?
Serina Therapeutics has 300.00% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is SER a Buy, Sell or Hold?
Serina Therapeutics has a consensus rating of Moderate Buy which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
What is Serina Therapeutics’s price target?
The average price target for Serina Therapeutics is 11.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $11.00 ,the lowest forecast is $11.00. The average price target represents 300.00% Increase from the current price of $2.75.
The highest analyst price target is $11.00 ,the lowest forecast is $11.00. The average price target represents 300.00% Increase from the current price of $2.75.
What do analysts say about Serina Therapeutics?
Serina Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
How can I buy shares of SER?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.